全文获取类型
收费全文 | 2287篇 |
免费 | 297篇 |
出版年
2021年 | 24篇 |
2019年 | 12篇 |
2018年 | 28篇 |
2017年 | 15篇 |
2016年 | 28篇 |
2015年 | 60篇 |
2014年 | 67篇 |
2013年 | 95篇 |
2012年 | 121篇 |
2011年 | 127篇 |
2010年 | 76篇 |
2009年 | 67篇 |
2008年 | 127篇 |
2007年 | 103篇 |
2006年 | 78篇 |
2005年 | 78篇 |
2004年 | 80篇 |
2003年 | 77篇 |
2002年 | 65篇 |
2001年 | 64篇 |
2000年 | 74篇 |
1999年 | 63篇 |
1998年 | 30篇 |
1997年 | 20篇 |
1996年 | 32篇 |
1995年 | 28篇 |
1994年 | 26篇 |
1993年 | 26篇 |
1992年 | 46篇 |
1991年 | 48篇 |
1990年 | 49篇 |
1989年 | 58篇 |
1988年 | 52篇 |
1987年 | 56篇 |
1986年 | 38篇 |
1985年 | 44篇 |
1984年 | 46篇 |
1983年 | 32篇 |
1982年 | 26篇 |
1981年 | 31篇 |
1980年 | 17篇 |
1979年 | 50篇 |
1978年 | 26篇 |
1977年 | 17篇 |
1976年 | 21篇 |
1975年 | 17篇 |
1974年 | 17篇 |
1973年 | 25篇 |
1972年 | 18篇 |
1971年 | 20篇 |
排序方式: 共有2584条查询结果,搜索用时 281 毫秒
151.
The aim of this article was to construct a T–ϕ phase diagram for a model drug (FD) and amorphous polymer (Eudragit® EPO) and to use this information to understand the impact of how temperature–composition coordinates influenced the final properties of the extrudate. Defining process boundaries and understanding drug solubility in polymeric carriers is of utmost importance and will help in the successful manufacture of new delivery platforms for BCS class II drugs. Physically mixed felodipine (FD)–Eudragit® EPO (EPO) binary mixtures with pre-determined weight fractions were analysed using DSC to measure the endset of melting and glass transition temperature. Extrudates of 10 wt% FD–EPO were processed using temperatures (110°C, 126°C, 140°C and 150°C) selected from the temperature–composition (T–ϕ) phase diagrams and processing screw speed of 20, 100 and 200rpm. Extrudates were characterised using powder X-ray diffraction (PXRD), optical, polarised light and Raman microscopy. To ensure formation of a binary amorphous drug dispersion (ADD) at a specific composition, HME processing temperatures should at least be equal to, or exceed, the corresponding temperature value on the liquid–solid curve in a F–H T–ϕ phase diagram. If extruded between the spinodal and liquid–solid curve, the lack of thermodynamic forces to attain complete drug amorphisation may be compensated for through the use of an increased screw speed. Constructing F–H T–ϕ phase diagrams are valuable not only in the understanding drug–polymer miscibility behaviour but also in rationalising the selection of important processing parameters for HME to ensure miscibility of drug and polymer.KEY WORDS: DSC, Flory–Huggins theory, hot-melt extrusion, thermal processing 相似文献
152.
153.
154.
155.
Alex A. Pollen Aparna Bhaduri Madeline G. Andrews Tomasz J. Nowakowski Olivia S. Meyerson Mohammed A. Mostajo-Radji Elizabeth Di Lullo Beatriz Alvarado Melanie Bedolli Max L. Dougherty Ian T. Fiddes Zev N. Kronenberg Joe Shuga Anne A. Leyrat Jay A. West Marina Bershteyn Craig B. Lowe Bryan J. Pavlovic Arnold R. Kriegstein 《Cell》2019,176(4):743-756.e17
156.
157.
158.
Andrews R Rosa L Daines M Khurana Hershey G 《Journal of immunology (Baltimore, Md. : 1950)》2001,166(3):1716-1722
IL-13 is a Th2-derived pleiotropic cytokine that recently was shown to be a key mediator of allergic asthma. IL-13 mediates its effects via a complex receptor system, which includes the IL-4R alpha-chain, IL-4Ralpha, and at least two other cell surface proteins, IL-13Ralpha1 and IL-13Ralpha2, which specifically bind IL-13. IL-13 has been reported to have very limited effects on mouse B cells. It was unclear whether this was due to a lack of receptor expression, a disproportionate relative expression of the receptor components, or an additional subunit requirement in B cells. To determine the requirements for IL-13 signaling in murine B cells, we examined IL-13-dependent Stat6 activation and CD23 induction in the murine B cell line, A201.1. A201.1 cells responded to murine IL-4 via the type I IL-4R, but were unresponsive to IL-13, and did not express IL-13 receptor. B220(+) splenocytes also failed to signal in response to IL-13 and did not express IL-13 receptor. We transfected A201.1 cells with human IL-4Ralpha, IL-13Ralpha1, or both. Transfectants expressing either human IL-4Ralpha or human IL-13Ralpha1 alone were unable to respond or signal to IL-13. Thus, human IL-13Ralpha1 could not combine with the endogenous murine IL-4Ralpha to generate a functional IL-13R. However, cells transfected with both human IL-4Ralpha and IL-13Ralpha1 responded to IL-13. Thus, the relative lack of IL-13 responsiveness in murine B cells is due to a lack of receptor expression. Furthermore, the heterodimeric interaction between IL-4Ralpha and IL-13Ralpha1 is species specific. 相似文献
159.
Kurnick JT Ramirez-Montagut T Boyle LA Andrews DM Pandolfi F Durda PJ Butera D Dunn IS Benson EM Gobin SJ van den Elsen PJ 《Journal of immunology (Baltimore, Md. : 1950)》2001,167(3):1204-1211
We have observed that malignant melanoma cells produce a soluble protein factor(s), which down-regulates melanocyte lineage Melan-A/MART-1 Ag expression by melanoma cells with concomitant loss of recognition by Melan-A/MART-1-specific T cells. This down-modulation of Melan-A/MART-1 expression, which we refer to as "Ag silencing," is mediated via its minimal promoter, whereas the promoter for the restricting Ag-presenting HLA-A2 molecule is not affected. Significantly, this Ag silencing is reversible, as removal of factor-containing supernatants from Melan-A/MART-1-expressing cells results in up-regulation of the promoter for the gene encoding this Ag, and renewed expression of the protein. We have evaluated over 20 known factors, none of which accounts for the Ag-silencing activity of the melanoma cell culture supernatants. The existence of this autocrine pathway provides an additional novel explanation for melanoma tumor progression in vivo in the presence of CTL specific for this melanocyte lineage Ag. These observations may have important implications for Melan-A/MART-1-specific CTL-mediated immunotherapy of melanoma tumors. 相似文献
160.
Hermes-Lima M Santos NC Yan J Andrews M Schulman HM Ponka P 《Biochimica et biophysica acta》1999,1426(3):475-482
The search for effective iron chelating agents was primarily driven by the need to treat iron-loading refractory anemias such as beta-thalassemia major. However, there is a potential for therapeutic use of iron chelators in non-iron overload conditions. Iron can, under appropriate conditions, catalyze the production of toxic oxygen radicals which have been implicated in numerous pathologies and, hence, iron chelators may be useful as inhibitors of free radical-mediated tissue damage. We have developed the orally effective iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and demonstrated that it inhibits iron-mediated oxyradical formation and their effects (e.g. 2-deoxyribose oxidative degradation, lipid peroxidation and plasmid DNA breaks). In this study we further characterized the mechanism of the antioxidant action of PIH and some of its analogs against *OH formation from the Fenton reaction. Using electron paramagnetic resonance (EPR) with 5, 5-dimethyl-1-pyrroline-N-oxide (DMPO) as a spin trap for *OH we showed that PIH and salicylaldehyde isonicotinoyl hydrazone (SIH) inhibited Fe(II)-dependent production of *OH from H2O2. Moreover, PIH protected 2-deoxyribose against oxidative degradation induced by Fe(II) and H2O2. The protective effect of PIH against both DMPO hydroxylation and 2-deoxyribose degradation was inversely proportional to Fe(II) concentration. However, PIH did not change the primary products of the Fenton reaction as indicated by EPR experiments on *OH-mediated ethanol radical formation. Furthermore, PIH dramatically enhanced the rate of Fe(II) oxidation to Fe(III) in the presence of oxygen, suggesting that PIH decreases the concentration of Fe(II) available for the Fenton reaction. These results suggest that PIH and SIH deserve further investigation as inhibitors of free-radical mediated tissue damage. 相似文献